Pathways Underlying Aggressive Breast Cancers
|
|
- Briana Arleen Dorsey
- 5 years ago
- Views:
Transcription
1 Origin of Breast Cancer Subtypes Pathways Underlying Aggressive Breast Cancers HER2 and ER can be expressed in any subtype. Triple Negative -- a mixture of subtypes Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology Pratt and Perou, Nature Med 15:842, 29 Triple Negative Breast Cancer is Biologically Heterogeneous Prat and Perou, Mol Oncol211 Prognostic Impact of Residual Disease Differs by Subtype Liedtke, C, et al J Clin Oncol 26:1275, 28 1
2 Meta-analysis of First-line Bevacizumab Plus Chemotherapy in Triple-negative Breast Cancer: Efficacy Bevacizumab + chemo (n = 363) Chemo alone (n = 258) HR (95% CI) This meta-analysis represents the largest reported population of patients randomized to treatment for metastatic TNBC The addition of bevacizumab significantly improved PFS, but not Do tumor-related symptoms improve with ORR and improved PFS? P value Median PFS (mo) ( ) <.1 ORR (%) NR <.1 Median (mo) ( ) yr rate NR.114 O Shaughnessy et al. SABCS 21; abstract P Capecitabine ± Ixabepilone in Triple Negative MBC Rugo et al. SABCS 28, Abstract 357 Pooled triple negative subgroup (n = 443) Efficacy Ixa + Cape (n = 191) Cape (n = 28) ORR 31% 15% CR 3% 1% PR 28% 14% Median PFS 4.2 mos 1.7 mos HR.63 P value <.1 Median 1.3 mos (n = 213) HR.87 P value mos (n = 23) EMBRACE: Overall survival subsets Overall results (N=762) Hazard ratio (95% CI) Phase II Polymer-Conjugated Irinotecan in A/T-pretreated MBC Receptor status No. of organs involved Sites of disease ER/PR + (n=528) ER/PR - (n=187) HER2 + (n=123) HER2 - (n=565) ER/PR/HER2 - (n=144) 2 (n=537) >2 (n=217) Visceral (n=624) Non-visceral (n=13) Favors ERIBULIN Favors TPC ITT population; Twelves, CJ, SABCS, 21, abst P Based upon a stratified Cox analysis including geographic region, HER-2/neu status, and prior capecitabine therapy as strata Awada, A, et al Proc SABCS, 21, P Normal Breast Luminal A Claudin-low Luminal B Basal-like HER2-enriched Mechanisms of DNA Double Strand Break Repair TNBC Molecular Targets? 2% TNBC BRCA1/2 mutations Gonzales-Angulo, A. ASCO Breast, 21, abst 16 Cells with BRCA mutations are deficient in homologous recombination and lack the ability to efficiently repair DSBs. Sehl, ME, et al. Clin Cancer Res 15:2192, 29 2
3 Iniparib* (BSI-21) A novel, investigational, anti-cancer agent In triple negative breast cancer cell lines 1-4 : Induces cell cycle arrest in the G2/M phase Induces double strand DNA damage γ H2AX foci but does not inhibit PARP 1 and 2 at physiologic drug concentrations Potentiates cell-cycle arrest induced by DNA damaging agents, including platinum and gemcitabine Physiologic targets of iniparib and its metabolites are under investigation Clinical Data: In a randomized phase 2 study, addition of iniparib to gemcitabine/carboplatin improved CBR, ORR, PFS and in patients with mtnbc 5 No potentiation of chemotherapy-related toxicities when iniparib is combined with gemcitabine/carboplatin *Iniparib is the United States Adopted Name (USAN) for the investigational agent BSI Ossovskaya V, et al. SABCS 21, San Antonio, TX. Poster P5-6-9; 2. Ossovskaya V, et al. AACR 29, Denver, CO. Abstract 5552; 3. Ossovskaya V, et al. AACR 211, Orlando, FL. Abstract LB-41; 4. Ji et al. AACR 211, Orlando, FL. Abstract 4527; 5. O Shaughnessy J, et al. N Engl J Med 211; 364: Schema Study Design: Multi-center, randomized open-label Phase III Trial Study Population: Stage IV TNBC ECOG PS 1 Stable CNS metastases allowed -2 prior chemotherapies for mtnbc Randomization stratified by prior chemo in the metastatic setting: 1 st -line (no prior therapy) 2 nd /3 rd -line (1-2 prior therapies) N = 519 R Gem/Carbo (GC) (N= 258) Gemcitabine 1 mg/m 2 IV d 1, 8 Carboplatin AUC2 IV d 1, 8 21-day cycles Gem/Carbo + Iniparib (GCI) (N= 261) Gemcitabine - 1 mg/m2 IV d 1, 8 Carboplatin - AUC2 IV d 1, 8 Iniparib mg/kg IV d 1,4,8,11 21-day cycles *Prospective central radiology review of progression required prior to crossover Crossover allowed to GCI following Disease Progression* (central review) 96% (n=152) of progressing patients crossed over to GCI at time of primary analysis NCT Probability of Progression Free Survival Efficacy Endpoints ITT population GC PFS (N=258) Median PFS, mos 4.1 (95% CI) (3.1, 4.6) GCI (N=261) 5.1 (4.2, 5.8) 1. HR (95% CI) p-value.79 (.65,.98).27.9 Pre-specified alpha = Since Study Entry GC GCI Probability of Survival Median, mos (95% CI) GC GCI (N=258) (N=261) (9.2, 12.1) (1.6, 12.9) HR (95% CI).88 (.69, 1.12) p-value 8 Pre-specified alpha = GC GCI O Shaughnessy et al. ASCO 211 abstr. 17 Probability of Progression Free Survival Exploratory Analysis 1 st -line ITT Population 1 st -line = 57% of patients (297/519) PFS 1. GCI 5.6 mos (4.2, 6.9).9 GC 4.6 mos (3.9, 5.7) HR=.88 (.66, 1.13); 197 events GC GCI Probability of Survival 1. GCI 12.4 mos (1.6, NE).9 GC 12.6 mos (11.9, NE) HR=1.1 (.78, 1.56); 129 events O Shaughnessy et al. ASCO 211 abstr Probability of Progression Free Survival Exploratory Analysis 2 nd /3 rd -line ITT Population 2 nd / 3 rd -line = 43% patients (222/519) PFS 1. GCI 4.2 mos (3.8, 5.7).9 GC 2.9 mos (1.9, 4.1 ) HR=.67 (.5,.92); 169 events GC GCI O Shaughnessy et al. ASCO 211 abstr. 17 Probability of Survival 1. GCI 1.8 mos (9.7,13.1).9 GC 8.1 mos (6.6, 1) HR=.65 (.46,.91); 132 events TNBC comprised of diverse molecular subtypes Relative frequency in panel basal claudinlow ERBB2 luminala luminalb normallike * Validation ongoing Affymetrix gene expression profiling of FFPE samples Intrinsic subtypes assigned using Sorlie et al, PNAS, 23 data set and claudin-low classifier (Prat et al., BCR, 21) [courtesy of J. Theilhaber and D. Bergstrom, Sanofi] Preliminary* 3
4 Subtypes of TNBC Pathway Activation in TNBC Subtypes Lehmann, BD, et al Lehmann, BD, et al.sabcs, 21 Pathways in TNBC Subtypes Rodriguez A and Chang J, et al. SABCS, 29 Rodriguez A, et al. SABCS, 29; 11 Rodriguez A, et al. SABCS, 29; 11 Mendes-Pereira. EMBO Mol Med 1:315, 29 Rodriguez Sourisseau A and T. Chang EMBO J, Mol et Med al. SABCS, 2:13, DNA SS and DS Repair Pathways ATM Kinase Cell Cycle Checkpoint Control and DNA Damage ATM heterozygous breast cancers increased sensitivity to radiation and increased late fibrosis ATM kinase protein expression evaluated in 113 BRCA1/2 WT breast cancers 2% TNBC ATM deficient Chk-2/ATM deficiency enhances sensitivity camptothecins in CRC 73% of 47 primary TNBCs pchk-2 deficient on TMA Plummer R. Clin Ca Res 16: 4527, 21 Tommiska J. Oncogene 27:251, 28 Sakasai R. J Biol Chem 285:1521, 21 4
5 Survival in Early Breast Cancer MMR-deficiency and breast cancer MMR-deficient Breast Cancer High grade/ki-67, more LN-, confluent necrosis; peritumor lymphocytes, less LVI, 6% TN, all HER2- CRC:Resistant to 5-FU, cis/carboplatin CRC:Sensitive to oxaliplatin, camptothecins, etoposide Jiang H, Genes & Development 23:1895, 29 MSH2 mutation synthetic lethal with methotrexate Other mutations CRC: TGFbR2, Walsh, MD. Clin Cancer Res 16:2214, 21 Vilar E. Clin Cancer Res 15:2829, 29 IGF2R, PTEN, RAD5, ATR, p53 15% CRC MMR-deficient and are Martin, SA. 1158/ CCR sensitive to PI3K pathway inhibitors MLH1 expression predicts prognosis following preop chemotherapy in LABC DNA Repair Proteins Associated with Time to Recurrence in TNBC Mackay H, et al. J Clin Oncol 18:87-93, 2 Alexander, BM, et al Clin Cancer Res 16:5796, 21 DNA Damage Response in TNBC Subtypes Loss of HR capacity (BRCA/ATM pathways) with dependence on DNA-PK & Base Excision Repair highly unstable genomes; very highly proliferative high sensitivity to DNA-damaging cytotoxic agents and PARP inhibitors? iniparib? higher pcr rates Mesenchymal TNBC - strong survival pathways Resistant to DNA-damaging agents Luminal B, claudin low? Targets? Randomized Phase II Irinotecan/Carboplatin + Cetuximab (anti-egfr MAb) Stage IV breast cancer, unselected population: Arm 1 Irinotecan+carbo. PD cetuximab Randomized Phase II Arm 2 Irinotecan+Carboplatin +cetuximab IC IC+E All subjects 21/69 (31%) 26/69 (38%) Triple Negative 1/33 (3%) 19/39 (49%) ER+ 1/35 (29%) 7/28 (25%) IC IC+E O Shaughnessy J et al, SABCS 7 5
6 MAPK and PI3K Pathways In Basal Breast Cancer EGFR Pathway Cetuximab Benefit in TNBC: PTEN+ and CRYAB-low PTEN-positive + CRYAB-Low Profile Chemotherapy PTEN IHC & CRYAB qpcr : ICb Chemotherapy + Cetuximab PTEN IHC & CRYAB qpcr: ICb+C n HR 95% CI p PTEN-pos & CRYAB-low other 1 1 ref n HR 95% CI p PTEN-pos & CRYAB-low other 17 1 ref MEK/ERK Growth, migration, apoptosis, differentiation, adhesion Only 8% mtnbc are both PTEN+ and CRYAB-low Carey, L and O Shaughnessy, J, et al. SABCS 29 Metastatic TNBC Durable Response with Cetuximab 34 yo woman third trimester pregnancy with left breast mass, infraclavicular adenopathy and lung metastases, grade 3 TNBC No response to preop AC Post-partum CR breast, nodes, lung with ICb + E lumpectomy and radiation + continued E 2 years later resection of solitary recurrent lung metastasis -- very low expression PTEN 6 cycles ICb + E and continues E for 2.5+ yrs DAT clinical activity: MpBC Metaplastic MBC generally chemotherapyresistant >5% PI3K mutations or PTEN loss DAT: Pegylated liposomal doxorubicin, bevacizumab, temsirolimus Response in 1 evaluable patients: 3% Complete Response (CR)=1 Partial Response (PR)=2 Sarcomatoid MpBC predominant responders SD> 6 months (1), CR (1), PR (2): 4% Moulder, S. AACR, 211 and J Clin Oncol 29:e572-5, 211 Complete Response in MpBC Partial Response in MpBC Baseline 2 nd cycle Baseline PI3K/PTEN Mutation status: None detected 8 cycles + Temsirolimus x 1year Moulder, S. AACR, 211 and J Clin Oncol 29:e572-5, of 9 pts had PI3K mutation or PTEN deletion PI3K/PTEN Mutation status: Not done Moulder, S. J Clin Oncol 29:e572-5, 211 6
7 USON # 9133 TGEN Drug Development Services Life Technologies Triple Negative Breast Cancer Sequencing Study Next Generation Whole Genome Sequencing Identifying and Targeting Driving Mutations in mtnbc Primary Objective: Treat patients with targeted agents identified on DNA and RNA sequencing tumor and normal tissue Conclusions Both lineage and specific mutation drivers of the TNBC subtypes Basal, mesenchymal (claudin low or luminal B?), apocrine MMR-deficient breast cancers --?role of irinotecan, methotrexate, oxaliplatin BRCA or ATM/ATR-deficient breast cancers may benefit from PARP inhibitors and DSB-inducing cytotoxic agents MAPK pathway and PI3K pathway amplicons/deletions worthy of dual targeting trials FOXM1 and AURKA highly active in TNBC targets? 7
ENFERMEDAD AVANZADA Qué hacemos con el triple negativo? Nuevas aproximaciones
ENFERMEDAD AVANZADA Qué hacemos con el triple negativo? Nuevas aproximaciones Javier Cortes, Hospital Universitario Ramon y Cajal, Madrid Vall d Hebron Institute of Oncology (VHIO), Barcelona Triple Negative
More informationTriple Negative Breast Cancer: Part 2 A Medical Update
Triple Negative Breast Cancer: Part 2 A Medical Update April 29, 2015 Tiffany A. Traina, MD Breast Medicine Service Memorial Sloan Kettering Cancer Center Weill Cornell Medical College Overview What is
More informationBreast : ASCO Abstracts for Review
Breast : ASCO 2011 Susana Campos, MD, MPH Dana Farber Cancer Institute Abstracts for Review Prevention Neoadjuvant Metastatic Brain mets LBA 504: Exemestane for primary prevention of breast cancer in postmenopausal
More informationAlternativas terapéuticas en fenotipo triple negativo Javier Cortes, Hospital Universitario Ramon y Cajal, Madrid
Alternativas terapéuticas en fenotipo triple negativo Javier Cortes, Hospital Universitario Ramon y Cajal, Madrid Vall d Hebron Institute of Oncology (VHIO), Barcelona Triple Negative Breast Cancer Immunohistochemistry
More informationTriple Negative Breast Cancer. Eric P. Winer, MD Dana-Farber Cancer Institute Harvard Medical School Boston, MA October, 2008
Triple Negative Breast Cancer Eric P. Winer, MD Dana-Farber Cancer Institute Harvard Medical School Boston, MA October, 2008 Triple Negative Breast Cancer 15% 25% Triple Negative 20% HER2+ ER+ Low Grade
More informationSubtype-directed therapy of TNBC Global Breast Cancer Conference 2015 & 4th International Breast Cancer Symposium Jeju Island, Korea, April 2015
Subtype-directed therapy of TNBC Global Breast Cancer Conference 2015 & 4th International Breast Cancer Symposium Jeju Island, Korea, April 2015 Ruth M. O Regan, MD Visiting Professor and Division Chief
More informationClinical Research on PARP Inhibitors and Triple-Negative Breast Cancer (TNBC)
Clinical Research on PARP Inhibitors and Triple-Negative Breast Cancer (TNBC) Eric P Winer, MD Disclosures for Eric P Winer, MD No real or apparent conflicts of interest to disclose Key Topics: PARP and
More informationTriple negative breast cancer 2014 GASCO Annual meeting September 5 th 2014, Atlanta, GA
Triple negative breast cancer 2014 GASCO Annual meeting September 5 th 2014, Atlanta, GA Ruth M. O Regan, MD Professor and Vice-Chair for Educational Affairs, Department of Hematology and Medical Oncology,
More informationTriple-Negative Breast Cancer
June 2017 Triple-Negative Breast Cancer Amir Sonnenblick, MD, PhD Sharett institute of oncology Hadassah-Hebrew university medical center, Jerusalem, Israel This presentation is the intellectual property
More informationEdith A. Perez, Ahmad Awada, Joyce O Shaughnessy, Hope Rugo, Chris Twelves, Seock-Ah Im, Carol Zhao, Ute Hoch, Alison L. Hannah, Javier Cortes
BEACON: A Phase 3 Open-label, Randomized, Multicenter Study of Etirinotecan Pegol (EP) versus Treatment of Physician s Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously
More information非臨床試験 臨床の立場から 京都大学医学部附属病院戸井雅和
資料 2 2 非臨床試験 臨床の立場から 京都大学医学部附属病院戸井雅和 1 Preclinical studies Therapeutic Window: Efficacy/Toxicity Disease Specificity Subtype Specificity Combination: Concurrent/Sequential Therapeutic situation: Response/
More informationContemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer
Contemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer Hope S. Rugo, MD Professor of Medicine Director, Breast Oncology and Clinical Trials Education University of California
More informationTriple Negative Breast cancer New treatment options arenowhere?
Triple Negative Breast cancer New treatment options arenowhere? Ofer Rotem, M.D., B.Sc. Breast Unit, Davidoff center Rabin Medical center October 2017 Case 6/2013 - M.D., 38 years old woman, healthy, no
More informationNovel Chemotherapy Agents for Metastatic Breast Cancer. Joanne L. Blum, MD, PhD Baylor-Sammons Cancer Center Dallas, TX
Novel Chemotherapy Agents for Metastatic Breast Cancer Joanne L. Blum, MD, PhD Baylor-Sammons Cancer Center Dallas, TX New Chemotherapy Agents in Breast Cancer New classes of drugs Epothilones Halichondrin
More informationOverview. Presentation and prognosis Outcomes with standard therapy
Emerging Therapies for Triple Negative Breast Cancer Joseph A. Sparano, MD Director, Breast Evaluation Center Montefiore-Einstein Cancer Center Professor of Medicine & Women s Health Albert Einstein i
More informationAdvances in Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings. Eve Rodler, MD University of California at Davis October 2016
Advances in Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings Eve Rodler, MD University of California at Davis October 2016 17th Annual Advances in Oncology September 30-October 1, 2016
More informationImmunotherapy for Breast Cancer. Aurelio B. Castrellon Medical Oncology Memorial Healthcare System
Immunotherapy for Breast Cancer Aurelio B. Castrellon Medical Oncology Memorial Healthcare System Conflicts Research support : Cascadian therapeutics, Puma biotechnology, Odonate therapeutics, Pfizer,
More informationGene Signatures in Breast Cancer: Moving Beyond ER, PR, and HER2? Lisa A. Carey, M.D. University of North Carolina USA
Gene Signatures in Breast Cancer: Moving Beyond ER, PR, and HER2? Lisa A. Carey, M.D. University of North Carolina USA When Are Biomarkers Ready To Use? Same Rules for Gene Expression Panels Key elements
More informationFinding the Positives in Triple-Negative Breast Cancer:
Finding the Positives in Triple-Negative Breast Cancer: A Three-Part Live CME Webcast Series Seminar I Wednesday, March 3, 2010 Faculty Clifford Hudis, MD Lisa A Carey, MD Seminar II Thursday, March 11,
More informationSystemic therapy of triple negative advanced breast cancer. Giuseppe Curigliano MD, PhD Breast Cancer Program Division of Early Drug Development
Systemic therapy of triple negative advanced breast cancer Giuseppe Curigliano MD, PhD Breast Cancer Program Division of Early Drug Development Outline State of the Art in the management of TN advanced
More informationUpdate on Breast Cancer
Update on Breast Cancer William J. Gradishar, MD Professor of Medicine Robert H. Lurie Comprehensive Cancer Center Feinberg School of Medicine Northwestern University Overview PARP Inhibitors Neoadjuvant
More informationCancer du sein métastatique et amélioration de la survie Pr. X. Pivot
Cancer du sein métastatique et amélioration de la survie Pr. X. Pivot Date of preparation: November 2015. EU0250i TTP/PFS Comparaisons First line metastatic breast cancer Monotherapy Docetaxel Chan 1999
More informationManagement of Triple Negative Breast Cancer. Giuseppe Curigliano MD, PhD University of Milano and European Institute of Oncology
Management of Triple Negative Breast Cancer Giuseppe Curigliano MD, PhD University of Milano and European Institute of Oncology Outline Heterogeneity of TNBC Targeting TNBC by subtypes New antibody drug
More informationLa malattia triplo negativa metastatica: quali trattamenti nella pratica clinica?
2018 CARCINOMA MAMMARIO: I TRAGUARDI RAGGIUNTI E LE NUOVE SFIDE La malattia triplo negativa metastatica: quali trattamenti nella pratica clinica? Roma, 27 Ottobre 2018 Relatore: Francesca Poggio Disclosure
More information4, :00 PM 9:00 PM
Consensus or Controversy? Clinical Investigators Provide Their Perspectives on Practical Issues and Research Questions in the Management of Breast Cancer Robert W Carlson, MD John Crown, MD Charles E Geyer
More informationSan Antonio Breast Cancer Symposium December 5-9, 2017
Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2-SN-38 Antibody-Drug Conjugate, as 3rd-line Therapeutic Option for Patients With Relapsed/Refractory Metastatic Triple-Negative Breast Cancer (mtnbc): Efficacy
More informationEmerging Therapies for Triple Negative Breast Cancer
Emerging Therapies for Triple Negative Breast Cancer Joseph A. Sparano, MD Professor of Medicine & Women s Health Albert Einstein College of Medicine Associate Chairman, Department of Oncology Montefiore
More informationPARP inhibitors for breast cancer
PARP inhibitors for breast cancer Mark Robson, MD Memorial Sloan Kettering Cancer Center Agenda Mechanism of action Clinical studies Resistance mechanisms Future directions Poly (ADP-ribose) Polymerases
More informationTargeting DNA repair in BRCA 1/2 and Triple Negative Breast Cancer
Targeting DNA repair in BRCA 1/2 and Triple Negative Breast Cancer Andrew Tutt, MB ChB, PhD Consultant Oncologist/Director Breakthrough Breast Cancer Research Unit King s Health Partners Academic Health
More information10/15/2012. Inflammatory Breast Cancer vs. LABC: Different Biology yet Subtypes Exist
Triple-Negative Breast Cancer: Optimizing Treatment for Locally Advanced Breast Cancer Beth Overmoyer MD Director, Inflammatory Breast Cancer Program Dana Farber Cancer Institute Overview Inflammatory
More informationRecent Update in Management of Breast Cancer: Medical Oncology. Jin Hee Ahn, M.D., PhD. 23-April-2015
2015 GBCC & 4 th IBCS 1/37 Recent Update in Management of Breast Cancer: Medical Oncology Jin Hee Ahn, M.D., PhD. 23-April-2015 Department of Oncology, Asan Medical Center, UUCM, Seoul, Korea 2/37 3/37
More informationTherapeutic Targets for Triple- Negative Breast Cancer: Focus on Platinums and EGFR Inhibition
Therapeutic Targets for Triple- Negative Breast Cancer: Focus on Platinums and EGFR Inhibition Lisa A Carey, MD Disclosures for Lisa A Carey, MD No real or apparent conflicts of interest to disclose Basal-Like
More informationBreast Cancer: ASCO Poster Review
Breast Cancer: ASCO Poster Review Carmen Criscitiello, MD, PhD Istituto Europeo di Oncologia Milano HER2+ SUBTYPE Research questions in early HER2+ BC De-escalation of toxicity without compromising efficacy
More informationL Oncologo Sperimentatore nel Disegno e nella Conduzione dello Studio Clinico
L Oncologo Sperimentatore nel Disegno e nella Conduzione dello Studio Clinico Antonino Musolino U.O.C. Oncologia Medica Azienda Ospedaliero-Universitaria di Parma LA SETTIMANA DEL GOIRC Negrar, 29 Aprile
More informationTNBC: What s new Déjà vu All Over Again? Lucy R. Langer, MD MSHS Compass Oncology - SABCS 2016 Review February 21, 2017
TNBC: What s new Déjà vu All Over Again? Lucy R. Langer, MD MSHS Compass Oncology - SABCS 2016 Review February 21, 2017 The problem with TNBC 1. Generally more aggressive 2. ONLY chemotherapy 3. No other
More informationBreast Cancer Immunotherapy. Leisha A. Emens, MD PhD Johns Hopkins University Bloomberg Kimmel Institute for Cancer Immunotherapy
Breast Cancer Immunotherapy Leisha A. Emens, MD PhD Johns Hopkins University Bloomberg Kimmel Institute for Cancer Immunotherapy Conflict of Interest I have the following financial relationships to disclose:
More informationSYSTEMIC THERAPY OPTIONS FOR BREAST CANCER IN 2014
SYSTEMIC THERAPY OPTIONS FOR BREAST Oncology Day 2014 CANCER IN 2014 Dr. Katherine Enright, M.D., M.P.H., F.R.C.P.(C) Katherine.enright@Trilliumhealthpartners.ca OBJECTIVES 1. Outline an approach to the
More informationEmerging Advances in Metastatic Breast Cancer
Emerging Advances in Metastatic Breast Cancer Bryan P. Schneider, MD Assistant Professor of Medicine & Medical Molecular Genetics IU Simon Cancer Center AT LEAST THREE types of breast cancer TNBC HER2+
More informationInterviews are based on data presented at the 2012 American Society of Clinical Oncology Annual Meeting, June 1-5, 2012, Chicago, Illinois* *PeerVoice is an independent publisher of conference news and
More informationCustomizing Therapeutic Strategies in the Management of Metastatic Breast Cancer
Customizing Therapeutic Strategies in the Management of Metastatic Breast Cancer Vandana G Abramson, MD Assistant Professor of Medicine Division of Hematology/Oncology Vanderbilt University Breast Cancer
More informationBreast cancer: Molecular STAGING classification and testing. Korourian A : AP,CP ; MD,PHD(Molecular medicine)
Breast cancer: Molecular STAGING classification and testing Korourian A : AP,CP ; MD,PHD(Molecular medicine) Breast Cancer Theory: Halsted Operative breast cancer is a local-regional disease The positive
More informationPost-ASCO 2017 Cancer du sein Triple Négatif
Post-ASCO 217 Cancer du sein Triple Négatif A.Ladjeroud, K.Bouzid Centre Pierre et Marie Curie- Alger Oran, 3 Septembre 217 Phase III Investigation of Neoadjuvant Carboplatin ± Veliparib in Combination
More informationMetastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
More informationNeoadjuvantTreatment In BC When, How, Who?
NeoadjuvantTreatment In BC When, How, Who? Clifford Hudis, M.D. Chief, Breast Cancer Medicine Service, MSKCC Professor of Medicine, Weill Cornell Medical College President, ASCO 15 Potential Benefits Of
More informationUpdate on the Management of HER2+ Breast Cancer. Christian Jackisch, MD, PhD Sana Klinikum Offenbach Offenbach, Germany
Update on the Management of HER2+ Breast Cancer Christian Jackisch, MD, PhD Sana Klinikum Offenbach Offenbach, Germany Outline Treatment strategies for HER2-positive metastatic breast cancer since First
More informationDR LUIS MANSO UNIDAD TUMORES DE MAMA Y GINECOLÓGICOS HOSPITAL 12 DE OCTUBRE MADRID
DR LUIS MANSO UNIDAD TUMORES DE MAMA Y GINECOLÓGICOS HOSPITAL 12 DE OCTUBRE MADRID RESUMEN DE ARTICULOS THERESA BOLERO 3 NOAH UP-DATE GEPAR SIXTO RADIOTHERAPY EBCTCG CTCs MISCELANEAS Lancet Oncol 2014;
More informationINMUNOTERAPIA EN CANCER COLORRECTAL METASTASICO. CCRm MSI-H NUEVO ESTANDAR EN PRIMERA LINEA Y/O PRETRATADOS?
INMUNOTERAPIA EN CANCER COLORRECTAL METASTASICO CCRm MSI-H NUEVO ESTANDAR EN PRIMERA LINEA Y/O PRETRATADOS? V. Alonso Servicio de Oncologia Medica H. U. Miguel Servet Zaragoza MSI-H mcrc Clinical and Pathological
More informationTNBC: Current Challenge and Perspectives. Henry L Gomez MD, PhD
TNBC: Current Challenge and Perspectives Henry L Gomez MD, PhD What Is a Triple-Negative Breast Cancer (TNBC)? Triple negative : ER negative, PgR negative, HER2 negative Depending on thresholds used
More informationASCO and San Antonio Updates
ASCO and San Antonio Updates 30 th Annual Miami Breast Cancer Conference March 7-10, 2013 Debu Tripathy, MD Professor of Medicine University of Southern California Norris Comprehensive Cancer Center Breakthroughs
More informationImmunoconjugates in Both the Adjuvant and Metastatic Setting
Immunoconjugates in Both the Adjuvant and Metastatic Setting Mark Pegram, M.D. Director, Stanford Breast Oncology Program Co-Director, Molecular Therapeutics Program Trastuzumab Treatment of Breast Tumor
More informationUnderstanding and Optimizing Treatment of Triple Negative Breast Cancer
Understanding and Optimizing Treatment of Triple Negative Breast Cancer Edith Peterson Mitchell, MD, FACP Clinical Professor of Medicine and Medical Oncology Program Leader, Gastrointestinal Oncology Department
More information10/15/2012. Biologic Subtypes of TNBC. Topics. Topics. Histopathology Molecular pathology Clinical relevance
Biologic Subtypes of TNBC Andrea L. Richardson M.D. Ph.D. Brigham and Women s Hospital Dana-Farber Cancer Institute Harvard Medical School Boston, MA Topics Histopathology Molecular pathology Clinical
More informationQuestion 1 A. ER-, PR-, HER+ B. ER+, PR+, HER2- C. ER-, PR+, HER2- D. ER-, PR-, HER2- E. ER-, PR+, HER2+
Triple Negative Breast Cancer Laura C. Collins, M.D. Department of Pathology Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA Question 1 The tumor depicted on the next slide
More informationTriple negative breast cancer -neoadjuvant and adjuvant systemic therapy
Triple negative breast cancer -neoadjuvant and adjuvant systemic therapy Sung-Bae Kim, MD, PhD Department of Oncology Asan Medical Center University of Ulsan College of Medicine Seoul, Korea DISCLOSURE
More informationGenomic tests to personalize therapy of metastatic breast cancers. Fabrice ANDRE Gustave Roussy Villejuif, France
Genomic tests to personalize therapy of metastatic breast cancers Fabrice ANDRE Gustave Roussy Villejuif, France Future application of genomics: Understand the biology at the individual scale Patients
More informationBiomarkers for HER2-directed Therapies : Past Failures and Future Perspectives
Biomarkers for HER2-directed Therapies : Past Failures and Future Perspectives Ian Krop Dana-Farber Cancer Institute Harvard Medical School Inchon 2018 Adjuvant Trastuzumab Improves Outcomes in HER2+ Breast
More informationMETRIC Study Key Eligibility Criteria
The METRIC Study METRIC Study Key Eligibility Criteria The pivotal METRIC Study is evaluating glembatumumab vedotin in patients with gpnmb overexpressing metastatic triple-negative breast cancer (TNBC).
More informationOverview and future horizons of PARP inhibitors in BRCAassociated. Judith Balmaña
Overview and future horizons of PARP inhibitors in BRCAassociated breast cancer Judith Balmaña PARP inhibitors: Mechanism of action Clinical development: Monotherapy In combination with chemotherapy Ongoing
More informationHER2-Targeted Rx. An Historical Perspective
HER2-Targeted Rx An Historical Perspective Trastuzumab: Front Line Rx for MBC Median 20.3 v. 25.1 mo P = 0.046 HR 0.8 65% of control patients crossed over Slamon D, et al. N Engl J Med, 2001; 344:783 Trastuzumab:Front-line
More informationTreatment of Metastatic TRIPLE NEGATIVE BREAST CANCERS. Rebecca Dent, MD FRCP (Canada) Senior Consultant, Medical Oncology
Treatment of Metastatic TRIPLE NEGATIVE BREAST CANCERS Rebecca Dent, MD FRCP (Canada) Senior Consultant, Medical Oncology Overview of TNBC Still best way to define in clinical practice!? Survival (%) Treatment
More informationEvolving Paradigms in HER2+ MBC: Strategies for Individualizing Therapy with Available Agents
Evolving Paradigms in HER2+ MBC: Strategies for Individualizing Therapy with Available Agents Kimberly L. Blackwell MD Professor Department of Medicine and Radiation Oncology Duke University Medical Center
More informationTargeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More informationSYSTEMIC TREATMENT OF TRIPLE NEGATIVE BREAST CANCER
SYSTEMIC TREATMENT OF TRIPLE NEGATIVE BREAST CANCER Sunil Shrestha 1*, Ji Yuan Yang, Li Shuang and Deepika Dhakal Clinical School of Medicine, Yangtze University, Jingzhou, Hubei Province, PR. China Department
More informationCONSIDERATIONS IN DEVELOPMENT OF PEMBROLIZUMAB IN MSI-H CANCERS
CONSIDERATIONS IN DEVELOPMENT OF PEMBROLIZUMAB IN MSI-H CANCERS December 2017 Christine K. Gause, Ph.D Executive Director, Biostatistics. 2 Microsatellite Instability-High Cancer - USPI KEYTRUDA is indicated
More informationMaintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute
Maintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute e.smit@nki.nl Evolution of front line therapy in NSCLC unselected pts
More informationRole of chemotherapy in BRCA and Triple negative breast cancer. Fernando Moreno Servicio de Oncología Médica Hospital Clinico San Carlos
Role of chemotherapy in BRCA and Triple negative breast cancer Fernando Moreno Servicio de Oncología Médica Hospital Clinico San Carlos Association between TNBC & germline mutations in BRCA 1/2 TNBC is
More informationSystemic Therapy Considerations in Inflammatory Breast Cancer
Systemic Therapy Considerations in Inflammatory Breast Cancer Shani Paluch-Shimon, MBBS, MSc Director, Breast Oncology Unit Shaare Zedek Medical Centre, Jerusalem Israel Disclosures Roche: Speakers bureau,
More informationHealth Disparities Advances in Breast Cancer Treatment. Jo Anne Zujewski April 27, 2009
Health Disparities Advances in Breast Cancer Treatment Jo Anne Zujewski April 27, 2009 Disclaimer Breast Cancer Incidence 1994-2003 Breast Cancer Mortality 1994-2003 Access to Care Comorbidity Biology
More informationAdvanced HER2+ Breast Cancer: New Options and How to Deploy Them. José Baselga MD, PhD
Advanced HER2 Breast Cancer: New Options and How to Deploy Them José Baselga MD, PhD HER2 signaling results in a multitude of cellular effects, including increased cellular proliferation HER2 HER3 RAS
More informationBest of San Antonio 2008
Best of San Antonio 2008 Ellie Guardino, MD/PhD Assistant Professor Stanford University BIG 1 98: a randomized double blind phase III study evaluating letrozole and tamoxifen given in sequence as adjuvant
More informationExpert Review: The Role of PARP Inhibition in the Treatment of Breast Cancer. Reference Slides
Expert Review: The Role of PARP Inhibition in the Treatment of Breast Cancer Reference Slides Overview BRCA Mutations and Breast Cancer Patients with BRCA mutations have an estimated 55% to 65% cumulative
More informationKarcinom dojke. PANEL: Semir Bešlija, Zdenka Gojković, Robert Šeparović, Tajana Silovski
Karcinom dojke PANEL: Semir Bešlija, Zdenka Gojković, Robert Šeparović, Tajana Silovski MBC: HER2 PHEREXA: Study Design Multicenter, randomized, open-label phase III trial Stratified by prior CNS disease,
More informationExpanding Therapeutic Strategies for HER2-Positive Metastatic Breast Cancer
Expanding Therapeutic Strategies for HER2-Positive Metastatic Breast Cancer Sara A. Hurvitz, MD, FACP Associate Professor of Medicine University of California Los Angeles Los Angeles, California Trastuzumab
More informationPrat et al, Mol Oncol 2011
Optimizing ther treatment of Triple Negative Breast Cancer: What Does the Future Hold? Ana M. Gonzalez-Angulo, M.D. Associate Professor Breast Medical Oncology Systems Biology Sao Paulo, Brazil, 3/2012
More informationNew Paradigms for Treatment of. Erminia Massarelli, MD, PHD, MS Clinical Associate Professor
New Paradigms for Treatment of Head and Neck cancers Erminia Massarelli, MD, PHD, MS Clinical Associate Professor City of Hope Disclosure Statement Grant/Research Support frommerck Bristol Grant/Research
More informationNew chemotherapy drugs in metastatic breast cancer. Guy Jerusalem, MD, PhD
New chemotherapy drugs in metastatic breast cancer Guy Jerusalem, MD, PhD MBC Patients survival over time Median survival increases over time, but is still measured in months This is not yet a chronic
More informationImmunotherapy for Breast Cancer Clinical Development
Immunotherapy for Breast Cancer Clinical Development Laurence Buisseret, MD, PhD Breast Cancer Translational Research Laboratory Institut Jules Bordet Université Libre de Bruxelles (ULB) ESMO preceptorship
More informationLung Cancer Case. Since the patient was symptomatic, a targeted panel was sent. ALK FISH returned in 2 days and was positive.
Lung Cancer Case Jonathan Riess, M.D. M.S. Assistant Professor of Medicine University of California Davis School of Medicine UC Davis Comprehensive Cancer Center 63 year-old woman, never smoker, presents
More informationMaintenance paradigm in non-squamous NSCLC
Maintenance paradigm in non-squamous NSCLC L. Paz-Ares Hospital Universitario Virgen del Rocío Sevilla Agenda Theoretical basis The data The comparisons Agenda Theoretical basis The data The comparisons
More informationBreast Cancer and Treatment Options in Patients with BRCA1/2 mutations. Olivia Pagani On behalf of Bella Kaufman
Breast Cancer and Treatment Options in Patients with BRCA1/2 mutations Olivia Pagani On behalf of Bella Kaufman Carrier Frequency Prevalence of an altered disease gene in a given population Background
More informationContemporary Classification of Breast Cancer
Contemporary Classification of Breast Cancer Laura C. Collins, M.D. Vice Chair of Anatomic Pathology Professor of Pathology Beth Israel Deaconess Medical Center and Harvard Medical School Boston, MA Outline
More informationImmunotherapy in the clinic. Lung Cancer. Marga Majem 20 octubre 2017
Immunotherapy in the clinic. Lung Cancer Marga Majem 20 octubre 2017 mmajem@santpau.cat Immunotherapy in the clinic. Lung Cancer Agenda Where we come from? Immunotherapy in Second line Immunotherapy in
More informationMalattia HER-2 positiva
Novità sul trattamento del carcinoma mammario Malattia HER-2 positiva Patrizia Vici Neoadjuvant - Adjuvant - Advanced Prognostic/Predictive factors..her-2 heterogeneity.. Neoadjuvant Phase II Pre-planned
More informationChoosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer
Choosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer Jyoti D. Patel, MD Associate Professor Feinberg School of Medicine Robert H Lurie Comprehensive Cancer Center Northwestern
More informationSponsor / Company: Sanofi Drug substance(s): SAR (iniparib)
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationImmunotherapy for the Treatment of Head and Neck Cancers. Robert F. Taylor, MD Aurora Health Care
Immunotherapy for the Treatment of Head and Neck Cancers Robert F. Taylor, MD Aurora Health Care Disclosures No relevant financial relationships to disclose I will be discussing non-fda approved indications
More informationIncorporating biologics in the management of older patients with metastatic colorectal cancer
Incorporating biologics in the management of older patients with metastatic colorectal cancer D Papamichael MB BS MD FRCP Cyprus Oncology Centre GSK Satellite Symposium SIOG APAC Singapore 12-13 July 2014
More informationCarrier Frequency. Breast Cancer and Treatment Options in Patients with BRCA1/2 mutations. Olivia Pagani On behalf of Bella Kaufman
Breast Cancer and Treatment Options in Patients with BRCA1/2 mutations Olivia Pagani On behalf of Bella Kaufman Carrier Frequency Prevalence of an altered disease gene in a given population 1 Background
More informationMolecular Classification of Triple-Negative Breast Cancer (TNBC) Aleix Prat, MD
Molecular Classification of Triple-Negative Breast Cancer (TNBC) Emerging genomic and clinical data Aleix Prat, MD Postdoctoral Research Associate at Perou Lab Lineberger Comprehensive Cancer Center University
More information10/15/2012. Overcoming Endocrine Therapy Resistance. The Problem in ER+ Tumors is Endocrine Therapy Resistance
Overcoming Endocrine Therapy Resistance Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology Slide Credits: Hope Rugo, MD The Problem in ER+ Tumors is Endocrine Therapy Resistance
More informationManagement Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective
Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive
More informationEvolving Insights into Adjuvant Chemotherapy. Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology
Evolving Insights into Adjuvant Chemotherapy Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology 80 70 60 50 40 30 20 10 0 EBCTCG 2005/6 Overview Control Arms with No Systemic
More informationSesiones interhospitalarias de cáncer de mama. Revisión bibliográfica 4º trimestre 2015
Sesiones interhospitalarias de cáncer de mama Revisión bibliográfica 4º trimestre 2015 Selected papers Prospective Validation of a 21-Gene Expression Assay in Breast Cancer TAILORx. NEJM 2015 OS for fulvestrant
More informationTherapeutic Options for Patients with BRAF-mutant Metastatic Colorectal Cancer
Therapeutic Options for Patients with BRAF-mutant Metastatic Colorectal Cancer Axel Grothey, M.D., Professor of Oncology, Clinical and Translational Science Division of Medical Oncology Mayo Clinic, Rochester,
More informationCáncer de mama HER2+/RE+ vs HER2+/RE : Una misma enfermedad? Dra E. Ciruelos Departamento de Oncología Médica Hospital Universitario 12 de Octubre
Cáncer de mama HER2+/RE+ vs HER2+/RE : Una misma enfermedad? Dra E. Ciruelos Departamento de Oncología Médica Hospital Universitario 12 de Octubre Recurrence of HER2-positive breast cancer (A) Time to
More informationOvercoming resistance to endocrine or HER2-directed therapy
Overcoming resistance to endocrine or HER2-directed therapy Jane Lowe Meisel, MD Assistant Professor of Hematology and Medical Oncology Winship Cancer Institute at Emory University 1 Background While most
More informationConsiderations in Adjuvant Chemotherapy. Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology
Considerations in Adjuvant Chemotherapy Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology 80 70 60 50 40 30 20 10 0 EBCTCG 2005/6 Overview Control Arms with No Systemic Treatment
More informationDieta Brandsma, Department of Neuro-oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands
What is hot in breast cancer brain metastases? Dieta Brandsma, Department of Neuro-oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands 8th Annual Brain Metastases Research and Emerging Therapy
More informationXII Michelangelo Foundation Seminar
XII Michelangelo Foundation Seminar The opportunity of the neoadjuvant approach L. Gianni, Milan, I XII Michelangelo Foundation Seminar Milano, October 12, 2012 The opportunity of the neoadjuvant approach
More informationPROGNOSTICO DE PACIENTES COM CA DE MAMA METASTATICO HER2+: PODEMOS FAZER MAIS? TDM-1 AND BEYOND!
II Simpósio Internacional de Câncer de Mama para o Oncologista Clínico PROGNOSTICO DE PACIENTES COM CA DE MAMA METASTATICO HER2+: PODEMOS FAZER MAIS? TDM-1 AND BEYOND! INGRID A. MAYER, MD, MSCI Assistant
More information